These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 10518655

  • 1. Optimizing oral absorption of peptides using prodrug strategies.
    Borchardt RT.
    J Control Release; 1999 Nov 01; 62(1-2):231-8. PubMed ID: 10518655
    [Abstract] [Full Text] [Related]

  • 2. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation.
    Gudmundsson OS, Nimkar K, Gangwar S, Siahaan T, Borchardt RT.
    Pharm Res; 1999 Jan 01; 16(1):16-23. PubMed ID: 9950273
    [Abstract] [Full Text] [Related]

  • 3. The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability.
    Gudmundsson OS, Vander Velde DG, Jois SD, Bak A, Siahaan TJ, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):403-13. PubMed ID: 10406218
    [Abstract] [Full Text] [Related]

  • 4. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers.
    Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, Borchardt RT.
    Pharm Res; 1999 Jan 01; 16(1):24-9. PubMed ID: 9950274
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers.
    Wang B, Nimkar K, Wang W, Zhang H, Shan D, Gudmundsson O, Gangwar S, Siahaan T, Borchardt RT.
    J Pept Res; 1999 Apr 01; 53(4):370-82. PubMed ID: 10406215
    [Abstract] [Full Text] [Related]

  • 6. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides.
    Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT.
    J Med Chem; 2006 Feb 23; 49(4):1261-70. PubMed ID: 16480263
    [Abstract] [Full Text] [Related]

  • 7. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability.
    Gudmundsson OS, Pauletti GM, Wang W, Shan D, Zhang H, Wang B, Borchardt RT.
    Pharm Res; 1999 Jan 23; 16(1):7-15. PubMed ID: 9950272
    [Abstract] [Full Text] [Related]

  • 8. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa.
    Nofsinger R, Borchardt RT.
    J Pharm Sci; 2012 Sep 23; 101(9):3500-10. PubMed ID: 22337204
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion.
    Ouyang H, Vander Velde DG, Borchardt RT, Siahaan TJ.
    J Pept Res; 2002 Apr 23; 59(4):183-95. PubMed ID: 11972752
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics.
    Ouyang H, Tang F, Siahaan TJ, Borchardt RT.
    Pharm Res; 2002 Jun 23; 19(6):794-801. PubMed ID: 12134949
    [Abstract] [Full Text] [Related]

  • 15. Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa.
    Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT.
    J Pharm Sci; 2009 Jan 23; 98(1):337-48. PubMed ID: 18537149
    [Abstract] [Full Text] [Related]

  • 16. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa.
    Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT.
    J Pharm Sci; 2009 Jan 23; 98(1):349-61. PubMed ID: 18537150
    [Abstract] [Full Text] [Related]

  • 17. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.
    Liederer BM, Borchardt RT.
    J Pharm Sci; 2005 Oct 23; 94(10):2198-206. PubMed ID: 16136552
    [Abstract] [Full Text] [Related]

  • 18. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: Synthesis of analogs designed to have improved stability to oxidative metabolism.
    Nofsinger R, Fuchs-Knotts T, Borchardt RT.
    J Pharm Sci; 2012 Sep 23; 101(9):3486-99. PubMed ID: 22411763
    [Abstract] [Full Text] [Related]

  • 19. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration.
    Liederer BM, Phan KT, Ouyang H, Borchardt RT.
    J Pharm Sci; 2005 Dec 23; 94(12):2676-87. PubMed ID: 16258984
    [Abstract] [Full Text] [Related]

  • 20. Characterization of the efflux transporter(s) responsible for restricting intestinal mucosa permeation of an acyloxyalkoxy-based cyclic prodrug of the opioid peptide DADLE.
    Tang F, Borchardt RT.
    Pharm Res; 2002 Jun 23; 19(6):780-6. PubMed ID: 12134947
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.